BRAF and neoplasm: Within the MSI-negative colorectal cancer set (n=991), tumours with BRAF and TP53 mutations had a particularly poor prognosis (HR 3·08 [95% CI 1·88–5·03]; p=7·12 × 10−6; figure 3; appendix p 27).